ArticleFrontiers in oncology2026
Epidemiological trends and patterns of Hodgkin lymphoma among Saudis.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hodgkin lymphoma is one of the most common malignancies reported in Saudi Arabia and is curable if detected early. An analysis of the epidemiology of Hodgkin lymphoma in Saudi Arabia may help identify epidemiological trends of the disease and, consequently, highlight potential areas for targeted interventions. Materials and methods: A retrospective population-based trend study was conducted to analyze data on the number of cases, age at diagnosis, gender, morphological subtypes, stage at diagnosis and regional distribution from 2011 to 2020, as published by the Saudi Cancer Registry (SCR). Descriptive statistical analyses were performed to evaluate temporal trends in incidence, stage distribution, morphological subtypes, and regional variation. Age-standardized incidence rates (ASR) were calculated using direct standardization. Temporal trends were assessed using log-linear regression to estimate the average annual percent change (APC). Results: A total of 4,563 cases of Hodgkin lymphoma were recorded over the span of the 10-year surveillance period. The proportion of Hodgkin lymphoma cases increased from 3.1% to 4.1% of cancer cases that were reported. The ASR increased from 1.8 to 2.7 per 100,000 individuals, accompanied by a statistically significant APC of +5.08% (p < 0.001). Male subjects exhibited a higher APC of +5.60% compared to females (+3.38%). A bimodal age distribution was observed, peaking at 15-19 years in males and 20-24 years in females. Morphologically, HL Not Otherwise Specified (NOS) showed a substantial increase from 13.6% to 56.2%, surpassing Nodular Sclerosis as the predominant subtype by the year 2020. While diagnoses at a distant stage remained prevalent, localized-stage diagnoses increased from 29.8% to 37.5% by 2018. Najran recorded the highest regional APC of +18.4%, whereas Madinah exhibited a notable and statistically significant decline of -4.3%. Conclusion: There is an increasing proportion of cancer cases attributable to Hodgkin lymphoma. The rising incidence of Hodgkin lymphoma is characterized by a shift toward the NOS (Not Otherwise Specified) subtype and significant geographical disparities. Furthermore, a trend toward diagnosis at earlier clinical stages suggests potential improvements in early detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.